Recent trials in immunosuppression and their consequences for current therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00058996" target="_blank" >RIV/00023001:_____/14:00058996 - isvavai.cz</a>
Result on the web
<a href="http://journals.lww.com/co-transplantation/pages/articleviewer.aspx?year=2014&issue=08000&article=00010&type=abstract" target="_blank" >http://journals.lww.com/co-transplantation/pages/articleviewer.aspx?year=2014&issue=08000&article=00010&type=abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MOT.0000000000000093" target="_blank" >10.1097/MOT.0000000000000093</a>

Result language
angličtina
Original language name
Recent trials in immunosuppression and their consequences for current therapy
Original language description
Purpose of review: Although the scarcity of clinical trials with de-novo immunosuppression has been typical over the last 2 years, several attempts have been made in drug conversion, dosing optimization, and bioequivalence. On the basis of recent clinical and animal studies, future directions of management and treatment are outlined. Recent findings: Studies with new tacrolimus formulations showed better bioavailability and lower doses, which might translate into less toxicity. The long-term results ofstudies with costimulation blockade confirmed their safety and efficacy. Calcineurin inhibitor (CNI)-free regimens based on mTOR inhibitors were shown to be associated with increased risk of the humoral response. Therefore, ongoing trials are predominantly designed to minimize calcineurin inhibitor dose only. Biologics, such as B-cell-specific agents (bortezomib and rituximab) and complement inhibitors (eculizumab) used to treat antibody-mediated rejection, recurrence of glomerulonephrit
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)